Literature DB >> 25890656

Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome.

Olle Ringdén1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25890656     DOI： 10.1016/S2213-2600(15)00047-8

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  3 in total

1.  Decidual stromal cell therapy for generalized lymphadenopathy as a special clinical manifestation of COVID-19 infection: A case report.

Authors:  Ali Pirsalehi; Masoud Soleimani; Abbas Hajifathali; Behnam Sadeghi; Behrouz Farhadihosseinabadi; Sedigheh Sadat Akhlaghi; Elham Roshandel
Journal:  Clin Case Rep       Date:  2022-05-16

2.  MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.

Authors:  Guido Moll; Norman Drzeniek; Julian Kamhieh-Milz; Sven Geissler; Hans-Dieter Volk; Petra Reinke
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

3.  Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.

Authors:  Olle Ringdén; Guido Moll; Britt Gustafsson; Behnam Sadeghi
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.